- Home
- IDYA vs ARWR Comparison
IDYA vs ARWR Comparison
Compare IDYA & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- ARWR
- Stock Information
- Founded
- IDYA 2015
- ARWR 2003
- Country
- IDYA United States
- ARWR United States
- Employees
- IDYA N/A
- ARWR N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- ARWR Biotechnology: Pharmaceutical Preparations
- Sector
- IDYA Health Care
- ARWR Health Care
- Exchange
- IDYA Nasdaq
- ARWR Nasdaq
- Market Cap
- IDYA 1.9B
- ARWR 1.8B
- IPO Year
- IDYA 2019
- ARWR 1993
- Fundamental
- Price
- IDYA $24.27
- ARWR $15.78
- Analyst Decision
- IDYA Strong Buy
- ARWR Buy
- Analyst Count
- IDYA 13
- ARWR 8
- Target Price
- IDYA $50.82
- ARWR $43.71
- AVG Volume (30 Days)
- IDYA 1.0M
- ARWR 2.0M
- Earning Date
- IDYA 08-05-2025
- ARWR 08-07-2025
- Dividend Yield
- IDYA N/A
- ARWR N/A
- EPS Growth
- IDYA N/A
- ARWR N/A
- EPS
- IDYA N/A
- ARWR N/A
- Revenue
- IDYA $7,000,000.00
- ARWR $545,209,000.00
- Revenue This Year
- IDYA $115.83
- ARWR $22,384.93
- Revenue Next Year
- IDYA $252.50
- ARWR N/A
- P/E Ratio
- IDYA N/A
- ARWR N/A
- Revenue Growth
- IDYA N/A
- ARWR 1436.97
- 52 Week Low
- IDYA $13.45
- ARWR $9.57
- 52 Week High
- IDYA $44.42
- ARWR $29.86
- Technical
- Relative Strength Index (RSI)
- IDYA 63.79
- ARWR 45.17
- Support Level
- IDYA $21.33
- ARWR $14.30
- Resistance Level
- IDYA $25.54
- ARWR $16.62
- Average True Range (ATR)
- IDYA 1.00
- ARWR 1.16
- MACD
- IDYA 0.20
- ARWR -0.30
- Stochastic Oscillator
- IDYA 70.60
- ARWR 29.45
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.